After-Hours Movers 03/27: (ZZ) (RBN) (NLST) Higher; (SNX) (KKR) Lower
Tweet
Share
E-mail
Get Alerts ZZ Hot Sheet
Join SI Premium – FREE
Sealy Corp. (NYSE: ZZ) 13.1% HIGHER; reported Q1 EPS of $0.01, $0.03 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $312.3 million versus the consensus estimate of $301.76 million.
Synnex Corp. (NYSE: SNX) 9.4% LOWER; reported Q1 EPS of $1.02, $0.10 better than the analyst estimate of $0.92. Revenue for the quarter came in at $2.46 billion versus the consensus estimate of $2.55 billion. Sees Q2 2012 EPS of $0.87-$0.91, versus the consensus of $0.95. Sees Q2 2012 revenue of $2.45-$2.55 million, versus the consensus of $2.6 million.
Robbins & Myers, Inc. (NYSE: RBN) 7.7% HIGHER; reported Q2 EPS of $0.84, $0.10 better than the analyst estimate of $0.74. Revenue for the quarter came in at $256 million versus the consensus estimate of $238.26 million. Sees Q3 2012 EPS of $0.80-$0.90, versus the consensus of $0.80. Sees FY2012 EPS of $3.40-$3.60, versus prior guidance of $3.00-$3.20 and the consensus of $3.20.
Netlist, Inc. (Nasdaq: NLST) 6% HIGHER; announced that the United States Patent and Trademark Office recently issued two favorable Office Actions in the reexaminations of US Pat. No. 7,532,537 ('537) and US Pat. No. 7,636,274 ('274). In the reexamination of the '537 patent, the USPTO allowed all 60 claims, while in the reexamination of the '274 patent, the USPTO allowed all 104 claims. By allowing these claims over the cited art, the USPTO rejected each and every prior art challenge raised by Inphi Corporation in its initial reexamination requests filed in June 2010, and subsequently during the reexamination proceedings of the '537 patent and the '274 patent. Inphi has a right to appeal these decisions.
KKR & Co. L.P. (NYSE: KKR) 1.5% LOWER; filed a registration with the U.S. Securities and Exchange Commission to sell, from time to time, up to 1.5 million Common Units.
Tompkins Financial Corporation (AMEX: TMP) 1.4% LOWER; announced today that it is commencing an underwritten public offering of $30 million of its common stock.
Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) 1.4% LOWER; filed a registration with the U.S. Securities and Exchange Commission to sell, from time to time, up to $150 million of Common Stock, Preferred Stock, Debt Securities, Warrants, Units, or any combination thereof.
Synnex Corp. (NYSE: SNX) 9.4% LOWER; reported Q1 EPS of $1.02, $0.10 better than the analyst estimate of $0.92. Revenue for the quarter came in at $2.46 billion versus the consensus estimate of $2.55 billion. Sees Q2 2012 EPS of $0.87-$0.91, versus the consensus of $0.95. Sees Q2 2012 revenue of $2.45-$2.55 million, versus the consensus of $2.6 million.
Robbins & Myers, Inc. (NYSE: RBN) 7.7% HIGHER; reported Q2 EPS of $0.84, $0.10 better than the analyst estimate of $0.74. Revenue for the quarter came in at $256 million versus the consensus estimate of $238.26 million. Sees Q3 2012 EPS of $0.80-$0.90, versus the consensus of $0.80. Sees FY2012 EPS of $3.40-$3.60, versus prior guidance of $3.00-$3.20 and the consensus of $3.20.
Netlist, Inc. (Nasdaq: NLST) 6% HIGHER; announced that the United States Patent and Trademark Office recently issued two favorable Office Actions in the reexaminations of US Pat. No. 7,532,537 ('537) and US Pat. No. 7,636,274 ('274). In the reexamination of the '537 patent, the USPTO allowed all 60 claims, while in the reexamination of the '274 patent, the USPTO allowed all 104 claims. By allowing these claims over the cited art, the USPTO rejected each and every prior art challenge raised by Inphi Corporation in its initial reexamination requests filed in June 2010, and subsequently during the reexamination proceedings of the '537 patent and the '274 patent. Inphi has a right to appeal these decisions.
KKR & Co. L.P. (NYSE: KKR) 1.5% LOWER; filed a registration with the U.S. Securities and Exchange Commission to sell, from time to time, up to 1.5 million Common Units.
Tompkins Financial Corporation (AMEX: TMP) 1.4% LOWER; announced today that it is commencing an underwritten public offering of $30 million of its common stock.
Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX) 1.4% LOWER; filed a registration with the U.S. Securities and Exchange Commission to sell, from time to time, up to $150 million of Common Stock, Preferred Stock, Debt Securities, Warrants, Units, or any combination thereof.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Shake Shack (SHAK) Announces Resignation of Jonathan Sokoloff from Board, Cuts Board Size to 10 from 11
- Soligenix, Inc. (SNGX) Prices $4.75 Million Public Offering
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
Create E-mail Alert Related Categories
Special ReportsRelated Entities
After-Hours MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
